Closing the gap: Modelling benefits of AAV scale-up using novel enhancers

Thursday 08:00 PST / 11:00 EST / 16:00 GMT / 17:00 CET

Sponsor

Closing the gap: Modelling benefits of AAV scale-up using novel enhancers

Cell and gene therapy manufacturing costs are a significant obstacle to the broader application of these life-saving therapies. Insufficient yield is a key contributor as demand continues to outpace supply. Innate antiviral defenses have emerged as an industry-wide issue impeding viral vector yield and quality.

BioSolve bioprocess modeling allows for the evaluation of benefits of enhancing technologies such as Viral Sensitizers (VSE™) by observing key cost drivers and identifying how they are influenced by even modest improvements in yield. Incorporating VSEs allows for robust scale-up of AAV8, and BioSolve unravels cost benefits for informed decision-making.

The impact of innate antiviral defenses on viral vector yield and quality
An overview of the mode of action and benefits of VSEs
A case study demonstrating how VSEs can enhance AAV8 yield and scale-up efficiency
Employing bioprocess modeling to determine long-term cost benefits of VSE-mediated enhancement of AAV in HEK293 cells

Jean-Simon Diallo

CEO at Virica Biotech

Dr Jean-Simon Diallo, PhD, is a scientist with broad expertise in biochemistry, molecular biology, cancer therapeutics and viral immunology. Dr. Diallo is an internationally recognized expert in oncolytic virotherapy and was seminal in the discovery of Viral Sensitizers and their development for virus manufacturing and cancer therapy applications in combination with oncolytic viruses.

Jondavid De Jong

VP, Scientific Operations at Virica Biotech

Dr Jondavid de Jong, PhD, is an industry expert with over 20 years of bench experience in the fields of virology, molecular biology, oncology and nanoparticle research. As Vice President of Scientific Operations at Virica Biotech, he leads a team of highly skilled scientists and business development professionals who are dedicated to helping biotech and CDMO organizations make viral medicines a reality

Andrea Vervoort

Technical Lead at Virica Biotech

Andrea Vervoort is a scientific professional with experience in the fields of bioprocess engineering and gene therapy production. As a Technical Lead at Virica Biotech, she is a subject matter expert in viral sensitizer (VSE) technology and is responsible for providing technical guidance and support during client evaluations of Virica’s technology. She also develops data-driven models of gene therapy production processes that provide strategic insight into process optimization.

Prior to joining Virica in 2020, Andrea was with the Ottawa Hospital Research Institute as a Cancer Therapeutics Research Assistant in the lab run by Dr. Jean-Simon Diallo, now CEO and Scientific Founder of Virica Biotech. She holds a Bachelor of Applied Science in Chemical Engineering from Queen’s University, with a concentration in Biochemical Engineering.